Efficacy and Safety of Finerenone in Asian Patients with Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis
<p>Introduction: In FIDELITY, a prespecified pooled analysis of the phase III FIDELIO-DKD and FIGARO-DKD trials, finerenone reduced the risk of cardiovascular (CV) and kidney events versus placebo in patients with type 2 diabetes and chronic kidney disease, on optimized renin-angiotensin...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Karger Publishers
2025-01-01
|
| Серии: | Kidney Diseases |
| Online-ссылка: | https://karger.com/article/doi/10.1159/000545415 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|